Core Viewpoint - Shanghai Haili Biological Technology Co., Ltd. is facing potential delisting risk due to insufficient operating income and negative net profit, primarily attributed to accounting treatment differences related to a significant refund from an acquisition [1][2][3] Financial Performance - The company announced an expected profit of 34 million to 40 million yuan for 2025, with a net profit attributable to shareholders projected between 11 million to 16 million yuan. However, it anticipates a net loss of 3.9 billion to 4 billion yuan after excluding non-recurring gains and losses, with revenue expected to be below 300 million yuan [2] - A refund of approximately 399.3 million yuan is impacting the company's financials, stemming from a re-evaluation of the acquisition of Shaanxi Ruisheng Biotechnology Co., Ltd. [3] Business Strategy - The company plans to pivot towards the dental sector, focusing on oral implants and clinics, anticipating growth in this area due to an aging population [1][4] - Haili Biological has already made strategic acquisitions in the dental industry, leveraging existing sales channels and resources from Ruisheng to promote its own implant products [7] Market Conditions - Ruisheng's profitability declined sharply in 2025 due to increased competition and a significant drop in product prices, with a 40% decrease in product prices reported in the second quarter [4][5] - The tightening of tax incentives and increased competition in the dental market have contributed to Ruisheng's financial struggles, leading to a reassessment of its valuation [5][6] Future Outlook - The company is optimistic about its future performance, expecting that new acquisitions will contribute positively to revenue by 2026, despite current delisting risks [7]

Core Viewpoint - The acquisition of Rui Sheng Biological by Haili Biological has led to unexpected valuation declines and questionable client relationships, raising concerns about financial transparency and potential misrepresentation in disclosures [1][3][5]. Group 1: Acquisition and Valuation - Haili Biological acquired 55% of Rui Sheng Biological for 935 million yuan, valuing the company at 1.711 billion yuan, representing a 952% increase in book value [1]. - Rui Sheng Biological's valuation was subsequently revised down to 974 million yuan, reflecting a 43% drop within eight months post-acquisition due to declining performance [1][2]. Group 2: Client Relationships and Disclosures - Wuhan He Mu Medical Technology, registered in April 2023, was listed as Rui Sheng Biological's largest client for 2022, raising questions about the legitimacy of this relationship [3][4]. - The explanation provided by Haili Biological regarding the client relationship was deemed insufficient by financial experts, suggesting potential financial misrepresentation [5][6]. - A second client, Shandong Quanming Medical, initially listed as a major client, later denied any collaboration with Rui Sheng Biological, further complicating the company's client disclosure credibility [9][10][11]. Group 3: Industry Context and Performance - Rui Sheng Biological's products, particularly in the dental implant repair materials sector, had previously seen rapid growth due to favorable market conditions and increased demand post-COVID-19 [22][23]. - However, the company faced significant challenges in 2025, including a 50%-60% price drop in bone powder products and increased competition, leading to a substantial decline in revenue and profit [23][24].

Core Insights - The acquisition of Rui Sheng Biological by Haili Biological has led to unexpected valuation adjustments, with Rui Sheng's valuation dropping from 1.7 billion RMB to 974 million RMB due to performance declines [7][18] - The presence of a company that was not yet established as a major client of Rui Sheng raises questions about the accuracy of financial disclosures [9][11] - The investigation revealed inconsistencies in client relationships and potential issues with financial reporting practices [20][21] Group 1 - Haili Biological acquired 55% of Rui Sheng Biological for 935 million RMB, resulting in a valuation increase of 952% at the time of acquisition [7] - Rui Sheng Biological's valuation was subsequently revised downwards due to declining performance, with a projected valuation of 974 million RMB by June 2025 [7][18] - The company claims to be a leading player in the market for natural calcined bone repair materials, particularly in dental applications [7] Group 2 - Wuhan He Mu Medical Technology, a client listed by Rui Sheng, was found to have been established only in April 2023, raising questions about its status as a major client [10][11] - The explanation provided by Haili Biological regarding the client relationship was deemed insufficient by financial experts, suggesting potential financial misrepresentation [11][18] - The investigation into client relationships revealed that actual business dealings may have been misrepresented, with claims of shared operations between different entities [13][15] Group 3 - The performance of Rui Sheng Biological has been adversely affected by increased competition and price wars, leading to a significant drop in revenue and profit margins [42][43] - The company reported a revenue of 26.77 million RMB and a net profit of 9.29 million RMB in Q3 2025, indicating a substantial decline compared to previous quarters [42] - Haili Biological plans to expand its operations by acquiring stakes in dental chain companies, which is expected to positively impact its financial performance in 2026 [43][44]

Core Viewpoint - The acquisition of Rui Sheng Biological by Haili Biological, which was expected to enhance performance, has instead led to a significant valuation drop and questionable client disclosures, raising concerns about potential financial misrepresentation [2][6][7]. Group 1: Acquisition and Valuation - Haili Biological acquired 55% of Rui Sheng Biological for 935 million RMB, valuing the company at 1.7 billion RMB, representing a 952% increase in value [6]. - Following a performance decline, Rui Sheng Biological's valuation was revised down to 974 million RMB, nearly halving within eight months post-acquisition [6][10]. - Rui Sheng Biological is recognized as a hidden champion in Shaanxi Province, specializing in natural calcined bone repair materials [6]. Group 2: Client Disclosure Issues - A company that was registered in 2023, Wuhan Hemu, was listed as the largest client of Rui Sheng Biological for 2022, raising questions about the legitimacy of this disclosure [10][11]. - Haili Biological explained that the collaboration with Wuhan Hemu predates its official establishment, but this explanation has been challenged by financial experts [10][14]. - The actual business relationship appears to be with Wuhan Xin Hao Medical, which has a shared email address and phone number with Wuhan Hemu, suggesting potential misrepresentation [13][14]. Group 3: Customer Relationship Discrepancies - Shandong Quanming Medical, listed as a major client, denied any collaboration with Rui Sheng Biological, contradicting the company's disclosures [23][30]. - The legal representative of Shandong Quanming initially denied any partnership but later acknowledged that there had been some form of cooperation, although details were unclear [34][37]. - The discrepancies in client relationships and the nature of contracts raise concerns about the accuracy of financial reporting and potential regulatory implications [14][37]. Group 4: Industry Context and Performance - The dental implant market, particularly for bone powder, has seen significant demand due to post-COVID recovery and government policies promoting dental care [43][45]. - Rui Sheng Biological's revenue growth from 2021 to 2023 was reported at a compound annual growth rate of 84.59%, attributed to market conditions and product advantages [45]. - However, in 2025, the company faced a sharp decline in revenue and profit due to increased competition and price wars, with bone powder prices dropping by 50% to 60% [45].

Group 1 - The acquisition of Ruisheng Bio by Haili Bio has resulted in a significant valuation drop, with the company's estimated value reduced from 1.7 billion yuan to 974 million yuan due to performance decline [5][39] - Ruisheng Bio, identified as a "hidden champion" in Shaanxi Province, specializes in natural calcined bone repair materials and has established a leading market position in dental implant repair materials [5][39] - The financial performance of Ruisheng Bio has been questioned, particularly regarding its customer relationships, with a newly established company appearing as a major client before its official registration [6][9] Group 2 - Haili Bio acquired 55% of Ruisheng Bio for 935 million yuan, reflecting a 952% increase in value since the initial purchase of multiple companies, including Ruisheng Bio, for 35 million HKD [5][39] - The sales figures for Ruisheng Bio's major clients in 2022 and 2023 show discrepancies, with a significant portion of sales attributed to clients that were either newly established or claimed to have no prior relationship with Ruisheng Bio [8][20] - The investigation revealed that the actual business relationships and sales figures may not align with the disclosures made by Ruisheng Bio, raising concerns about potential financial misrepresentation [12][13] Group 3 - The competitive landscape in the dental implant market has intensified, leading to a drastic price drop of 50% to 60% for bone powder products, which has adversely affected Ruisheng Bio's revenue [38] - Despite a compound annual growth rate of 84.59% in revenue from 2021 to 2023, Ruisheng Bio reported a significant decline in revenue and profit in the third quarter of 2025 [37][38] - Haili Bio plans to expand its business by acquiring stakes in dental chain companies, which is expected to positively impact its revenue and profit in 2026 [39]

Core Insights - Haili Bio has reduced the acquisition price of 55% equity in Ruisheng Bio from 935 million yuan to 536 million yuan, with corresponding adjustments to performance commitments [1] - The adjusted profit commitments for 2025 and 2026 are set at 50 million yuan and 58 million yuan respectively, with a return of 399 million yuan expected from the transaction [1] - Ruisheng Bio's revenue for the first half of the year was 78.37 million yuan, with a net profit of 33.77 million yuan, both showing a decline year-on-year [1] Group 1 - The acquisition was completed in October last year, and the profit commitment for 2024 has already been met [1] - The valuation adjustment was initiated due to national policy impacts on the industry and tightening tax incentives, which affected the previously agreed equity value [1] - Ruisheng Bio's core products are natural calcined bone repair materials, and the company has faced a significant price drop in its oral product line, with a nearly 30% year-on-year decline in Q1 2025 and a 40% decline quarter-on-quarter in Q2 [1] Group 2 - Despite the performance decline, Ruisheng Bio remains an industry leader, with an increase in market share of approximately 6% to 7% for bone powder and bone membrane products compared to the same period last year [1] - The company has also submitted registration applications for two products in the first half of the year, indicating ongoing product development [1] - Haili Bio stated that the adjustment in valuation and price reduces investment costs and risks, while also mitigating the risk of failing to meet performance commitments, thereby protecting shareholder interests [1]

Core Viewpoint - The acquisition price of 55% stake in Ruisheng Bio by Haili Bio has been reduced from 935 million yuan to 536 million yuan due to the decline in Ruisheng Bio's operating performance, which helps to lower investment costs and control risks for the company and its shareholders [1][3] Group 1: Acquisition Details - Haili Bio announced the adjustment of the acquisition price for Ruisheng Bio's 55% stake from 935 million yuan to 536 million yuan, with corresponding adjustments to performance commitments for 2025 and 2026 [1] - The transaction was completed in October last year, and Ruisheng Bio has met its net profit commitment for 2024 [1] - The adjustment will result in a return of the price difference of 399 million yuan from the counterparty and is expected to reduce the goodwill formed during the acquisition [1] Group 2: Industry Context - Ruisheng Bio operates in the oral regenerative medicine sector, with its core product being natural calcined bone repair materials [2] - The industry is experiencing a "price war," with Ruisheng Bio's oral product line prices dropping nearly 30% year-on-year in Q1 2025 and a further 40% decline in Q2 [2] - Tax incentives previously applicable to Ruisheng Bio have been tightened, changing from a simplified VAT rate of 3% to a general rate of 13% [2] Group 3: Company Performance - Despite the challenges, Ruisheng Bio has increased its market share of bone powder and bone membrane products by approximately 6% to 7% due to increased shipment volumes from a new facility [2] - The company is awaiting acceptance of registration applications for two products, bone repair materials and natural bone repair materials [2] - Ruisheng Bio maintains a high gross margin while enhancing services, expanding sales to public hospitals, and optimizing internal costs [2][3]

Core Insights - The company, Haili Biological (603718.SH), reported a significant net profit increase of 172.28% in 2024, with non-recurring gains accounting for 93.82% of net profit, despite a revenue decline in Q1 2025 [2][5][8] - Haili Biological has transitioned from animal health products to human health products, leading to a substantial restructuring of its business model [2][9] Financial Performance - In 2024, Haili Biological's net profit reached approximately 1.71 billion yuan, with a notable increase attributed to asset disposals and acquisitions [4][5] - The company achieved an investment return exceeding 1 billion yuan from the sale of a 30% stake in WuXi Vaccines, which had previously generated low returns [5][6] - The sale of Yangling Jinhai at a nominal price of 1 yuan was a strategic move to eliminate ongoing losses, with the company recovering all debts owed by Yangling Jinhai [6][8] Asset Management - Haili Biological completed the acquisition of a 55% stake in Shaanxi Ruisheng Biotechnology, which is focused on oral tissue repair and regeneration materials, resulting in a goodwill of approximately 782 million yuan [9][10] - The company has prioritized finding quality projects in the oral and IVD sectors following the restructuring, although it acknowledges the challenges in identifying such opportunities [3][9] Market Dynamics - The oral vaccine market, particularly for foot-and-mouth disease, is facing increased competition and declining profitability, prompting Haili Biological to divest from Yangling Jinhai [7][8] - The revenue from Ruisheng Biotechnology in 2024 was approximately 265 million yuan, slightly below expectations, but the net profit exceeded targets [11]

Core Viewpoint - In 2024, Haili Biological (603718) underwent a significant strategic transformation by divesting long-term loss-making assets and acquiring the dental restoration materials company Ruisheng Biological, successfully shifting its focus to the human health sector. This transformation is reflected in a 172% year-on-year increase in net profit for 2024 and a turnaround to profitability in Q1 2025 with a net profit of 10.9 million yuan, a 393.11% increase year-on-year [1][2]. Group 1: Business Transformation - Haili Biological, originally established as a veterinary biological pharmaceutical factory, expanded into the human health sector in 2018 by acquiring IVD company Jiemen Biological, creating two main business segments: veterinary and IVD [2]. - The veterinary business faced continuous development pressure, leading to stagnant revenue since its IPO in 2015, which did not exceed 350 million yuan [2]. - In 2024, the company strategically adjusted its business layout by divesting loss-making veterinary assets and acquiring a 55% stake in Ruisheng Biological, focusing on high-tech dental restoration materials [2]. Group 2: Market Opportunity - Ruisheng Biological operates in a rapidly expanding market for dental implant restoration materials, benefiting from explosive demand and structural opportunities in China's dental healthcare market [3]. - Following the implementation of centralized procurement for dental implants in April 2023, the cost of a single dental implant dropped from tens of thousands to 4,000-6,000 yuan, stimulating demand [3]. - The dental implant market in China grew from approximately 27 billion yuan in 2022 to 38 billion yuan in 2023, with a projected growth to over 50 billion yuan in 2024 and 80 billion yuan by 2026 [3][4]. Group 3: Competitive Position - Ruisheng Biological has established a strong position in the domestic dental restoration materials market, with a market share that continues to rise and is accelerating the replacement of imported brands [5]. - The company’s bone repair products, made from bovine bone, and its collagen membranes have shown effective results in clinical applications, with a significant increase in sales volume [6]. - In 2023, Ruisheng Biological's bone powder sales grew by 138%, and in 2024, it is expected to continue growing by 61%, leading the market among domestic brands [6]. Group 4: Future Growth Potential - Ruisheng Biological is set to double its production capacity for bone powder from 800,000 bottles per year to 2 million bottles per year by 2025, with a 15% reduction in unit costs [6][7]. - The company is also expanding its collagen membrane production capacity and has achieved competitive pricing, winning bids in 95% of provinces under centralized procurement [7]. - Ruisheng Biological has committed to achieving a cumulative net profit of no less than 414 million yuan from 2024 to 2026, with 138 million yuan expected in 2024, indicating a feasible path to meet its performance commitments [7].